Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Pneumonia

Pneumonia Clinical Trial

Official title:

Open-label, Randomized, Controlled, With Blind Assessor, Study to Assess Efficacy and Safety of Rheosorbilact®, Solution for Infusion ("Yuria-Pharm"), in Comparison With Ringer's Lactate,Solution for Infusion, in a Complex Therapy of Pneumonia.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03824457
• Other study ID #: RheoSTAT-CP0698
• Status: Completed
• Phase: Phase 4
• Start date: January 8, 2018
• Est. completion date: February 17, 2020

Study information

• Verified date: October 2019
• Source: Yuria-Pharm
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates the efficacy and safety of Rheosorbilact®, solution for infusion ("Yuria-Pharm" LLC), in comparison with Ringer's Lactate, solution for infusion, in a complex therapy of pneumonia. Half of participants will receive Rheosorbilact® in complex therapy, while the other half will receive Ringer's Lactate in complex therapy.

Description:

Rheosorbilact® has rheological, anti-shock, detoxification, and alkalizing effects. Sorbitol and sodium lactate are the major pharmacologically active ingredients. In the liver, sorbitol is first converted into fructose, which is then converted into glucose, and then into glycogen. Part of sorbitol is used for urgent energy needs, while the other part is kept as a reserve in the form of glycogen. Isotonic sorbitol solution has a disaggregating effect and, therefore, improves microcirculation and tissue perfusion.

The management of metabolic acidosis with sodium lactate goes more slowly compared to bicarbonate solution, as far as sodium lactate enters the metabolic process; however the latter does not cause swings in pH values. The effect of sodium lactate is typically seen 20 to 30 minutes after administration.

Sodium chloride is a plasma-substituting agent that exhibits a detoxification and rehydration effect. It replenishes the deficiency of sodium and chlorine ions in various pathological conditions.

Calcium chloride replenishes deficiency of calcium ions. Calcium ions are essential in the transmission of nerve impulses, contraction of skeletal and smooth muscles, myocardial activity, bone tissue formation, and blood clotting. It reduces the permeability of cells and vascular walls, prevents the development of inflammatory reactions, enhances the resistance of the body to infections and can significantly boost phagocytosis.

Potassium chloride restores the water-electrolyte balance. It exhibits a negative chrono- and bathmotropic action and, when administered in high doses, has a negative ino- and dromotropic and moderate diuretic effect. It is involved in the process of nerve impulse conduction, increases the content of acetylcholine and causes excitation of the sympathetic segment of the autonomic nervous system and improves the contraction of skeletal muscles in subjects with muscular dystrophy or myasthenia.

Rheosorbilact® is administered to improve capillary blood flow for the prevention and treatment of traumatic, surgical, hemolytic, toxic and burn shock, acute blood loss, and burn disease; infectious diseases accompanied by intoxication, exacerbation of chronic hepatitis; sepsis, pre- and postoperative period to improve arterial and venous circulation for the prevention and treatment of thrombosis, thrombophlebitis, endarteritis, and Raynaud's disease.

Ringer's Lactate, solution for infusion will be used as a comparator. As a rehydrating agent, Ringer's Lactate has a detoxification effect, replenishes the deficiency of circulating blood volume, and stabilizes the water and electrolyte composition of blood. Ringer's Lactate normalizes the acid-base balance. Lactate is metabolized in the body to bicarbonate, so the solution has an alkalizing effect. With osmolarity at 273 mOsm/l, Ringer's Lactate is close to isotonic solution and is indicated for hypovolemia, isotonic dehydration, and metabolic alkalosis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 150
• Est. completion date: February 17, 2020
• Est. primary completion date: February 17, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Men and women aged 18 to 45 years inclusive;

2. Community-acquired pneumonia with a prescription from the beginning of antibacterial therapy no more than 48 hours;

3. The risk class of pneumonia in the PSI/PORT index score is at least IV;

4. Informed consent for participation in the study signed by subject's own hand.

5. The baseline value of the SOFA scale = 2 points.

Non-inclusion criteria:

1. Individual intolerance of the components of the study drug and reference preparation;

2. Hypersensitivity to sodium lactate;

3. Intravenous infusions of lactate- or sorbitol-containing products within 24 hours before enrollment;

4. Severe renal dysfunction (creatinine is more than 300 µmol/l or estimated creatinine clearance is less than 30 ml/min);

5. Pregnancy or breast-feeding;

6. Metabolic alkalosis;

7. Severe metabolic acidosis;

8. Intracerebral hemorrhage;

9. Any thromboembolism;

10. Decompensated cardiovascular failure;

11. Arterial hypertension III st;

12. Conditions associated with immunodeficiency (the use of cytostatics or system steroids, AIDS, diabetes mellitus);

13. Extracellular hyperhydration or hypervolemia;

14. Severe renal insuffiency (with oliguria/anuria);

15. Hyperkalemia;

16. Hypercalcemia;

17. Ascites associated with cirrhosis;

18. Conditions associated with increased lactate levels (hyperlactatemia > 2 mmol / l), including lactic acidosis, or impaired lactate uptake (including due severe hepatic insufficiency);

19. Concomitant therapy with cardiac glycosides.

Exclusion Criteria:

1. Infusion of the study drug or the comparator is started more than 12 hours after randomization;

2. Lack of data for community-acquired pneumonia (diagnosis not confirmed);

3. Withdrawal of the informed consent by the subject;

4. Investigator considers that the infusion therapy with either study drug or comparator may not be continued for safety reasons;

5. Development of conditions that prevent further use of the study drug/comparator before efficacy evaluation visit (Visit 3);

6. Subject needs concomitant therapy prohibited in the study before efficacy evaluation visit (Visit 3);

7. Development of conditions (including serious adverse events) which make it impossible to evaluate the primary endpoint;

8. Confirmation of pregnancy at any time of the study.

Related Conditions & MeSH terms

• Pneumonia

Intervention

Drug:
• Rheosorbilact®
Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours) for 3 days.
• Ringer lactate
Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours) for 3 days.

Locations

Country	Name	City	State
Georgia	"Unimedi Adjara" LLC	Batumi
Georgia	JSC EVEX Medical corporation/Kutaisi Referral Hospital	Kutaisi
Georgia	"Israel Georgian Medical Research Clinic HELSI Core LLC" LTD.	Tbilisi
Kazakhstan	Hospital of the Medical Center Office of the President's Affairs Republic of Kazakhstan	Astana
Moldova, Republic of	Municipal Clinical Hospital	Chisinau
Moldova, Republic of	Municipal Clinical Hospital "Sfinta Treime"	Chisinau
Ukraine	National institute of phthisiology and pulmonology named after F.G. Yanovsky NAMS of Ukraine	Kyiv
Ukraine	City Hospital ?1	Nikolaev
Ukraine	Vinnitsa National Medical University; City Clinical Hospital ?1	Vinnitsa
Uzbekistan	Republican Scientific Center of Emergency Medical Aid	Tashkent
Vietnam	198 Hospital	Hanoi
Vietnam	Thai Binh University of Medicine and Pharmacy	Thái Bình

Sponsors (1)

Lead Sponsor	Collaborator
Yuria-Pharm

Countries where clinical trial is conducted

Georgia,  Kazakhstan,  Moldova, Republic of,  Ukraine,  Uzbekistan,  Vietnam, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Incidence of Treatment-Emergent Adverse events.	All types of adverse events.	Patients will be followed during 14 days.
Other	Incidence of multiple organ failure.	Incidence of multiple organ failure.	Patients will be followed during 14 days.
Other	Overall survival (%) at follow-up visit.	Overall survival (%) at follow-up visit.	Patients will be followed during 14 days.
Primary	A change in the total SOFA score vs. baseline score upon admission;	Sequential Organ Failure Assessment (SOFA) score is composed of scores of six organ systems: R-respiratory, C-cardiovascular, H-hepatic, Co-coagulation, Re-renal, and N-neurological graded from 0 to 4 according to the degree of dysfunction or failure.; The SOFA score ranges from 0 to 24 points. We evaluate initial SOFA score and differences between subsequent scores (?-SOFA scores).	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	A change in the total APACHE II score vs. baseline score upon admission;	Acute physiology and chronic health evaluation(APACHE) II score is calculated from a patient's age (0-6 points) and 12 physiological parameters (each item 0-4 points): AaDO2 or PaO2 (depending on FiO2), Temperature (rectal), Mean arterial pressure, pH arterial, Heart rate, Respiratory rate, Sodium (serum), Potassium (serum), Creatinine, Hematocrit, White blood cell count, Glasgow Coma Scale and chronic disease health status (0-5 points).; The APACHE II score ranges from 0 to 71 points. We evaluate initial APACHE II score and differences between subsequent scores (?-APACHE II scores).	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	A change in the total SAPS II score vs. baseline score upon admission;	The SAPS II score is made of 17 variables: 12 physiology variables, age, type of admission (scheduled surgical, unscheduled surgical, or medical), and three underlying disease variables (acquired immunodeficiency syndrome, metastatic cancer, and hematologic malignancy).; The SAPS II score ranges from 0 to 160 points. We evaluate initial SAPS II score and differences between subsequent scores (?-SAPS II scores).	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	A change in the total MODS score vs. baseline score upon admission;	MODS (Multiple Organ Dysfunction Score) is composed of scores of six organ systems: R-respiratory, C-cardiovascular, H-hepatic, Co-coagulation, Re-renal, and N-neurological graded from 0 to 4 according to the degree of dysfunction or failure.; The MODS score ranges from 0 to 24 points. We evaluate initial MODS score and differences between subsequent scores (MODS scores).	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	A change in the total PSI/PORT score vs. baseline score upon admission	The Pneumonia severity index (PSI or PORT Score) for predicting the mortality in patients with pneumonia based on patients stratification into five classes of risk for death.; The lowest risk class (risk class I) comprises patients who are younger than 50 years of age, have none of the five important coexisting illnesses and have normal mental status and normal or only mildly abnormal vital signs at presentation. Assignment to the remaining risk classes depends on the presence or absence of a set of medical history, physical examination, and laboratory findings.; Total point scores of 70 or less correspond to class II, 71-90 to class III, 91-130 to class IV, and more than 130 to class V.	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	A change in the total CURB-65 score vs. baseline score upon admission	The CURB-65 score for predicting the mortality in patients with pneumonia is an acronym for each of the six risk factors measured: confusion status, serum urea, respiratory rate, blood pressure, and age.; Each risk factor scores one point, for a maximum score of 5.	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	Concentration of glucose	Concentration of glucose (mmol/L) in blood serum after 8-hour fasting.	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	Concentration of sodium	Concentration of sodium (mmol/L) in blood serum after 8-hour fasting.	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	Concentration of potassium	Concentration of potassium (mmol/L) in blood serum after 8-hour fasting.	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	Concentration of lactate	Concentration of lactate (mmol/L) in blood serum after 8-hour fasting.	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	Concentration of pyruvate	Concentration of pyruvate (mmol/L) in blood serum after 8-hour fasting.	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	Concentration of urea.	Concentration of urea (mmol/L) in blood serum after 8-hour fasting.	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	Concentration of creatinine.	Concentration of creatinine (µmol/L) in blood serum after 8-hour fasting.	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	Concentration of bilirubin.	Concentration of bilirubin (µmol/L) in blood serum after 8-hour fasting.	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	Concentration of alanine aminotransferase.	Concentration of alanine aminotransferase (U/L) in blood serum after 8-hour fasting.	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	Concentration of aspartate aminotransferase.	Concentration of aspartate aminotransferase (U/L) in blood serum after 8-hour fasting.	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	Concentration of lactate dehydrogenase.	Concentration of lactate dehydrogenase (U/L) in blood serum after 8-hour fasting.	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	Concentration of alkaline phosphatase.	Concentration of alkaline phosphatase (U/L) in blood serum after 8-hour fasting.	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	Concentration of ?-Glutamyltransferase.	Concentration of ?-Glutamyltransferase (U/L) in blood serum after 8-hour fasting.	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	Concentration of low-molecular-weight adiponectin (LMW).	Concentration of low-molecular-weight adiponectin (U/L) in blood serum after 8-hour fasting.	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	Concentration of middle-molecular-weight adiponectin (MMW).	Concentration of middle-molecular-weight adiponectin (U/L) in blood serum after 8-hour fasting.	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	Concentration of albumin.	Concentration of albumin in blood serum after 8-hour fasting.	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	Procalcitonin level.	Concentration of procalcitonin level (µg/L) in blood serum after 8-hour fasting.	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	White blood cells (WBC) count level.	White blood cells (billion/L) count level in blood serum after 8-hour fasting.	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	Lymphocyte count level.	Lymphocyte count (%) level in blood serum after 8-hour fasting.	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	Platelet count level.	Platelet count level (billion/L) in blood serum after 8-hour fasting. 2. assessment of ECG parameters; 3.parameters of central hemodynamics; 4. mental status: consciousness, intelligence, behavior, neuromuscular disorders.	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	Calculation of Nuclear index of intoxication (NII)	Calculated by dividing the number of myelocytes, young and stab neutrophils by number of segmented neutrophils.	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	Calculation of Leukocyte index of intoxication (LII).	Calculated by the formula of Kalf-Kalifa: correlation between the level of neutrophils and the content of other cells in the blood leukocytic composition.	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	Concentration of C-reactive protein (CRP).	Concentration of C-reactive protein (CRP) in blood serum after 8-hour fasting.	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	Level of circulating immune complexes (CIC).	Level of Circulating immune complexes (CIC) in blood serum after 8-hour fasting.	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	Concentration of Interleukin-1 and 2.	Concentration of Interleukin-1 (pg/ml) and Interleukin-2 (pg/ml) in blood serum after 8-hour fasting.	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	Calculation of neutrophil-to-lymphocyte ratio (NLR).	Calculated by dividing the number of neutrophils (%) by number of lymphocytes (%).	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	Concentration of immunoglobulins.	Concentration of Ig A, Ig M and Ig G in blood serum after 8-hour fasting.	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	Concentration of complements.	Concentration of complements (C3, C4) in blood sample after 8-hour fasting.	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	Assessment of central hemodynamics.	Measurement of central venous pressure (mmh2o) in the central vein.	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	A change in the total Glasgow Coma Scale (GCS) score vs. baseline score upon admission	The GCS is composed of 3 components: ocular response (assessment 1-4 points), motor response (assessment 1-6 points) verbal response (evaluation of 1-5 points). Scores for each component are added together to get the total that will range between a minimum of 3 points (which corresponds to a patient who does not open his eyes and no motor response to stimulation or verbal response) and a maximum value of 15 points (corresponding to a patient with open eyes, obeying orders and maintaining a consistent language).	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	Measurement of 12-lead electrocardiogram (ECG)	Measurement of 12-lead ECG with further evaluation and interpretation whether the ECG waves, intervals, durations and rhythm are normal.	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.
Secondary	Number of participants with Presence of clinical signs	Number of participants with presence of clinical signs such as adynamia, weakness, memory impairment, sleep disorder, irritability, evaluated according to patient's subjective complaints.	Will be evaluated for the duration of Intensive Care Unit (ICU) stay, at screening (Day 0) and Visit 3 (Day 3) of ICU stay.